Tumour necrosis factor alpha in non-inflammatory bowel disease enterocutaneous fistulas prospective study

被引：0
|
作者：
Rahbour, G. [1 ]
Al-Hassi, H. O. [1 ]
Hart, A. L. [1 ]
Ullah, M. R. [1 ]
Gabe, S. M. [1 ]
Knight, S. C. [1 ]
Warusavitarne, J. [1 ]
Vaizey, C. J. [1 ]
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Antigen Presentat Res Grp, St Marks Hosp & Acad Inst, London, England
来源：
IMMUNOLOGY | 2012年 / 137卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：536 / 537
页数：2
相关论文
共 50 条
  • [31] Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease
    Theis, V. S.
    Rhodes, J. M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (01) : 19 - 30
  • [32] Tumour necrosis factor α promoter polymorphisms influence disease phenotype and severity in childhood inflammatory bowel disease
    Van Limbergen, J
    Russell, RK
    Nimmo, ER
    Drummond, HE
    Anderson, N
    Wilson, DC
    Gillett, PM
    McGrogan, P
    Hassan, K
    Weaver, LT
    Bisset, WM
    Mahdi, G
    Satsangi, J
    GUT, 2006, 55 : A10 - A10
  • [33] Non-inflammatory small bowel infection induces colitis in mouse models of inflammatory bowel disease
    Dann, Sara
    Le, Christine
    Kim Nguyen
    Dann, Raymond
    Hanson, Elaine
    Eckmann, Lars
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S8 - S8
  • [34] Anti-tumour necrosis factor α antibodies and circulating lymphocyte phenotypes in inflammatory bowel disease
    Defendenti, Caterina
    Tarkowski, Maciej
    Borille, Simona
    Cassinotti, Andrea
    Massari, Alessandro
    Birindelli, Sarah
    Riva, Agostino
    Ardizzone, Sandro
    Panteghini, Mauro
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 100
  • [35] Tumour necrosis factor (TNF) antagonist therapy for paediatric inflammatory bowel disease: A systematic review
    Martin-Garcia, Paula
    Alonso-Arroyo, Adolfo
    Catala-Lopez, Ferran
    MEDICINA CLINICA, 2023, 160 (11): : 501 - 516
  • [36] Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients
    Mohabbat, A. B.
    Sandborn, W. J.
    Loftus, E. V., Jr.
    Wiesner, R. H.
    Bruining, D. H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (06) : 569 - 574
  • [37] How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease
    Naviglio, Samuele
    Giuffrida, Paolo
    Stocco, Gabriele
    Lenti, Marco Vincenzo
    Ventura, Alessandro
    Corazza, Gino Roberto
    Di Sabatino, Antonio
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 12 (08) : 797 - 810
  • [38] Does faecal calprotectin differentiate between inflammatory bowel disease colitis and non-inflammatory bowel disease colitides?
    Khalil, Ahmed F.
    Helmy, Ekram M.
    Massoud, Mohamed N.
    Baddour, Nahed M.
    Metwally, Rasha H.
    Omar, Omneya M.
    GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2021, 16 (03): : 219 - 223
  • [39] European guidelines for the use of anti-tumour necrosis factor agents in inflammatory bowel disease
    Kruis, W
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2001, 16 (01) : 12 - 13
  • [40] European guidelines for the use of anti-tumour necrosis factor agents in inflammatory bowel disease
    Wolfgang Kruis
    International Journal of Colorectal Disease, 2001, 16 : 12 - 13
12345